< Back to previous page
Researcher
Steven Simoens
- Disciplines:Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Clinical Pharmacology and Pharmacotherapy (Division)
Member
From1 Jul 2013 → Today
Projects
1 - 10 of 22
- How to create sustainable market access to advanced therapies?From1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- Health Economic Evaluations of Preventive Policies in Flanders (HELPPFL)From22 Nov 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Development, Validation, and Valorization of a Patient Preference Platform to Inform Healthcare Decision-MakingFrom1 Mar 2023 → TodayFunding: IOF - technology validation in lab
- Exploring the market access of advanced therapy medicinal products (ATMPs)From17 Oct 2022 → 9 Sep 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- STRAtified Dosing based on Augmented renal clearance for CEFtriaxone in patients with severe community-acquired pneumonia: STRADA-CEF trial.From1 Oct 2022 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Exploring the market environment of biologics including biosimilar medicinesFrom20 Sep 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Framework for value driven market access of gene therapyFrom1 Sep 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Unlocking Biosimilar Benefits: An Exploration of Barriers to Biosimilar Adoption, Value Assessment and Market SustainabilityFrom16 Oct 2019 → 13 Dec 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- A Belgian policy framework for best-value biological medicinesFrom3 Sep 2019 → 18 Sep 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Framework for value driven market access of gene therapyFrom1 Sep 2019 → 23 Oct 2020Funding: FWO Strategic Basic Research Grant
Publications
41 - 50 of 427
- Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications(2021)
Authors: Steven Simoens
Pages: 527 - 540 - Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians(2021)
Authors: Liese Barbier, Yannick Vandenplas, Steven Simoens, Paul Declerck, Arnold Vulto, Isabelle Huys
- Off-Patent Biologicals and Biosimilars Tendering in Europe—A Proposal towards More Sustainable Practices(2021)
Authors: Liese Barbier, Steven Simoens, Arnold Vulto, Isabelle Huys
- How to Value Orphan Drugs? A Review of European Value Assessment Frameworks(2021)
Authors: Alessandra Blonda, Yvonne Denier, Isabelle Huys, Steven Simoens
- How do biosimilars sustain value, affordability, and access to oncology care?(2021)
Authors: Steven Simoens
Pages: 327 - 329 - Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study(2021)
Authors: Steven Simoens, Arnold Vulto
- Methodological Quality Assessment of Budget Impact Analyses for Orphan Drugs: A Systematic Review(2021)
Authors: Khadidja Abdallah, Isabelle Huys, Kathleen Claes, Steven Simoens
- Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis(2021)
Authors: Yannick Vandenplas, Steven Simoens, Arnold Vulto, Isabelle Huys
- Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium(2021)
Authors: Steven Simoens
- Patient Preferences to Assess Value IN Gene Therapies: Protocol Development for the PAVING Study in Hemophilia(2021)
Authors: Steven Simoens, Isabelle Huys